Kura Oncology, Inc. (KURA)
10.60
+0.08
(+0.76%)
USD |
NASDAQ |
Oct 09, 16:00
10.75
+0.15
(+1.42%)
After-Hours: 06:32
Kura Oncology Cash from Investing (Quarterly) : 92.21M for June 30, 2026
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 92.21M |
| March 31, 2026 | -24.23M |
| December 31, 2025 | -64.60M |
| September 30, 2025 | 93.97M |
| June 30, 2025 | 58.94M |
| March 31, 2025 | -101.41M |
| December 31, 2024 | -94.96M |
| September 30, 2024 | 45.54M |
| June 30, 2024 | 43.17M |
| March 31, 2024 | -95.34M |
| December 31, 2023 | 42.20M |
| September 30, 2023 | 8.559M |
| June 30, 2023 | -46.33M |
| March 31, 2023 | 11.13M |
| December 31, 2022 | -47.32M |
| September 30, 2022 | 71.81M |
| June 30, 2022 | 33.10M |
| March 31, 2022 | -24.96M |
| December 31, 2021 | 74.06M |
| September 30, 2021 | 22.54M |
| June 30, 2021 | -37.22M |
| March 31, 2021 | -186.22M |
| December 31, 2020 | -60.19M |
| Date | Value |
|---|---|
| September 30, 2020 | -45.52M |
| June 30, 2020 | -21.69M |
| March 31, 2020 | 27.46M |
| December 31, 2019 | -15.26M |
| September 30, 2019 | -55.75M |
| June 30, 2019 | 8.876M |
| March 31, 2019 | 15.81M |
| December 31, 2018 | 4.618M |
| September 30, 2018 | -58.06M |
| June 30, 2018 | 3.857M |
| March 31, 2018 | -29.71M |
| December 31, 2017 | -4.091M |
| September 30, 2017 | -36.29M |
| June 30, 2017 | 7.433M |
| March 31, 2017 | 9.534M |
| December 31, 2016 | 9.68M |
| September 30, 2016 | 0.143M |
| June 30, 2016 | -5.842M |
| March 31, 2016 | 8.197M |
| December 31, 2015 | -40.45M |
| September 30, 2015 | -3.891M |
| June 30, 2015 | -26.28M |
| March 31, 2015 | -0.01M |
Cash From Investing Definition
Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Inovio Pharmaceuticals, Inc. | 6.147M |
| Fortress Biotech, Inc. | -0.079M |
| Spero Therapeutics, Inc. | 0.00 |
| Gossamer Bio, Inc. | 42.70M |
| ACADIA Pharmaceuticals, Inc. | -8.529M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -62.55M |
| Cash from Financing (Quarterly) | 1.499M |
| Free Cash Flow | -117.43M |
| Free Cash Flow Per Share (Quarterly) | -0.7113 |
| Free Cash Flow to Equity (Quarterly) | -63.39M |
| Free Cash Flow to Firm (Quarterly) | -62.86M |
| Free Cash Flow Yield | -12.55% |